First-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma

Area of Science:

• Oncology
• Hematology
• Clinical Trials

Background:

• First-line (1L) therapy for mantle cell lymphoma (MCL) is rapidly advancing.
• Novel covalent Bruton's tyrosine kinase inhibitor (cBTKi) combinations demonstrate significant activity in recent trials.

Purpose of the Study:

• To explore the selection of 1L therapy for MCL considering emerging cBTKi options.
• To analyze the benefits, limitations, and challenges of novel cBTKi regimens in MCL treatment.

Main Methods:

• Review of recent phase II and phase III clinical trials involving cBTKi combinations.
• Presentation and discussion of three illustrative patient cases for 1L therapy selection.
• Analysis of factors influencing treatment decisions, including MCL biology and patient risk tolerance.

Main Results:

• cBTKi combinations show consistent activity in MCL treatment.
• Traditional selection criteria may not fully apply to novel cBTKi regimens.
• Additional factors like MCL biology and patient risk are crucial for therapy selection.

Conclusions:

• The evolving landscape of MCL therapy requires a multifaceted approach to selecting 1L treatment.
• Patient-specific factors and emerging cBTKi options necessitate careful consideration for optimal outcomes.
• Further research is needed to address evidence gaps for these novel regimens.